Perceptive Advisors RGEN Position
Active5-Fund ConvergencePerceptive Advisors increased their position in Repligen Corporation (RGEN) in Q4 2025, holding $51.7M worth of shares across 315,541 shares.
The position was first reported in Q1 2025 and has been tracked across 4 quarterly 13F filings.
RGEN is a convergence signal: 5 specialist biotech funds hold this stock, suggesting high institutional conviction.
Short interest stands at 10.4% of float with 4.9 days to cover, indicating significant bearish positioning against Perceptive's long thesis.
About Repligen Corporation
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Full company profile →Short Interest
10.4%
4.9 days to cover
Perceptive Advisors RGEN Position History
Frequently Asked Questions
Does Perceptive Advisors own RGEN?
Yes. As of Q4 2025, Perceptive Advisors holds 315,541 shares of Repligen Corporation (RGEN) valued at $51.7M. This data comes from their SEC 13F filing.
How many hedge funds own RGEN?
5 specialist biotech hedge funds currently hold RGEN, including RTW Investments, Driehaus Capital, Eventide Asset Management and 1 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Perceptive Advisors first buy RGEN?
Perceptive Advisors's position in RGEN was first reported in Q1 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Perceptive Advisors's RGEN position increasing or decreasing?
Perceptive Advisors increased their RGEN position in the most recent quarter, adding 45,113 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
RGENCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Perceptive AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →